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Abstract
Patient-derived xenograft (PDX) models better represent human cancer than traditional cell lines. 
However, the complex in vivo environment makes it challenging to employ PDX models to 
investigate tumor-stromal interactions, such as those that mediate prostate cancer (PCa) bone 
metastasis. Thus, we engineered a defined three-dimensional (3D) hydrogel system capable of 
supporting the co-culture of PCa PDX cells and osteoblastic cells to recapitulate the PCa-
osteoblast unit within the bone metastatic microenvironment in vitro. Our 3D model not only 
maintained cell viability but also preserved the typical osteogenic phenotype of PCa PDX cells. 
Additionally, co-culture cellularity was maintained over that of either cell type cultured alone, 
suggesting that the PCa-osteoblast cross-talk supports PCa progression in bone, as is hypothesized 
to occur in patients with prostatic bone metastasis. Strikingly, osteoblastic cells co-cultured with 
PCa PDX tumoroids organized around the tumoroids, closely mimicking the architecture of PCa 
metastases in bone. Finally, tumor-stromal signaling mediated by the fibroblast growth factor axis 
tightly paralleled that in the in vivo counterpart. Together, these findings indicate that this 3D PCa 
PDX model recapitulates important pathological properties of PCa bone metastasis, and validate 
the use of this model for controlled and systematic interrogation of complex in vivo tumor-stromal 
interactions.
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Introduction
Given the heavy investment in understanding cancer over the past several decades, the high 
drug attrition rates in oncologic drug development are disappointing (1). The poor 
translation of seemingly promising preclinical findings to clinical success is partly due to the 
heavy reliance on cancer cell lines as tumor models for preclinical studies (2). Recently, 
patient-derived xenograft (PDX) models have emerged as better surrogates of human cancer. 
PDX models, developed through serial propagation of patient tumor tissue in murine hosts, 
closely resemble the parental tumor in histology, gene expression profiles, preserved 
heterogeneity, and drug response (3–7). However, use of PDX models in in vitro 
mechanistic studies is hampered by their poor adaptation to traditional two-dimensional 
tissue culture and the potential for two-dimensional culture to induce undesired adaptations 
(6,8). Improved methods for in vitro PDX culture have been developed that rely on three-
dimensional (3D) cell culture strategies, such as spheroid culture, or encapsulation of tumor 
cells within naturally derived gels such as Matrigel or collagen (9–12). However, while 
spheroid cultures enable primary tumor tissue culture, the lack of a surrounding matrix 
prohibits control over spatial positioning of multiple cell types. Similarly, the often ill-
defined and variable composition of naturally derived gels makes consistent re-creation of 
the engineered in vitro tumor microenvironment challenging.
In current paradigms, cancer is viewed as a complex manifestation of aberrant interactions 
between tumor cells and the surrounding stromal compartment. Accordingly, increasing 
emphasis is being placed on understanding the role of the host cells in the tumor 
microenvironment in cancer progression and metastasis and in design of therapies (13). In 
prostate cancer (PCa), stromal-epithelial signaling dictates tumor cell behavior and 
metastasis (14–16). Metastasizing PCa cells predominantly target bone, and the 
characteristic osteoblastic lesions that form reflect the functional dependency of PCa on the 
bone microenvironment for disease progression. Therefore, targeting the bone stroma and 
disrupting the PCa-stromal cross-talk can be an effective therapeutic strategy for treating or 
preventing bone metastases (17). In our recent integrated clinical and preclinical studies 
using the MDA PCa 118b PDX model, we demonstrated that blockade of fibroblast growth 
factor receptor (FGFR)-dependent PCa-stromal interactions in the bone microenvironment 
could be an effective therapeutic strategy for a subset of PCa patients (17). In light of these 
findings, we wished to further investigate the specific stromal targets and affected pathways 
to guide biomarker development and patient selection. However, in vitro platforms to 
support such mechanistic studies of PCa PDX-stromal interactions had to be created.
In the interdisciplinary study reported here, we addressed this need by developing and 
validating an in vitro PCa PDX model that accurately reflects PCa-stromal interactions in 
bone for controlled mechanistic studies. We demonstrate for the first time, to our 
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knowledge, an engineered tumor microenvironment consisting of clinically relevant PDX 
tumor cells and osteoblastic cells, co-encapsulated within a well-defined 3D hyaluronan 
(HA) hydrogel. Osteoblasts play a key role in promoting PCa progression in bone (18). 
Ubiquitous in the extracellular matrix of connective tissues, HA is a building block for the 
fabrication of hydrogel matrices designed to mimic HA-rich tissues such as the bone 
marrow, where bone metastatic PCa cells reside (19,20). Indeed, we previously reported the 
first demonstration of using a 3D scaffold-based approach to culture PDX cells in vitro in 
unmodified HA hydrogels (21). Prior to development of our 3D hydrogel approach, it was 
difficult to culture PCa PDX cells in vitro for experimentation given their poor viability on 
tissue culture plastic. In this work, to enable the culture of osteoblastic cells with PCa PDX 
cells, HA was specifically modified with integrinbinding peptides and cross-linked with 
matrix metalloproteinase (MMP)-degradable peptides. Plain, unmodified HA hydrogels are 
not capable of supporting the attachment and spreading of encapsulated osteoblastic cells. 
Incorporation of these peptides is an approach that was previously developed to enable cell-
mediated remodeling of synthetic 3D hydrogels for tissue regeneration applications (22–24). 
This PDX co-culture model maintains key phenotypic tumor markers; recapitulates the in 
vivo structural arrangement of osteoblasts with respect to tumor cells; mimics many 
elements of the previously observed FGFR-mediated tumor-stromal crosstalk for PDX 
tumor cells grown in bone, including cross-talk involving FGFR1 and fibroblast growth 
factor 9 (FGF9) (17,25); and offers a robust platform for in vitro drug evaluation. This 
model addresses the critical unmet need in PCa research and drug discovery for platforms 
that support the controlled interrogation of complex in vivo tumor-stromal interactions as 
discrete units in vitro.
Materials and Methods
Study design
The primary objective of this study was to develop an auxiliary model to the in vivo PCa 
PDX model that supports controlled mechanistic studies of tumor-stromal interactions in 
vitro. We cultured PCa PDX cells and osteoblastic cells within a well-defined 3D hydrogel 
matrix and characterized the tumor architecture, viability, phenotype, as well as the 
biochemical interaction between the two cell populations. These findings were then 
validated against the corresponding PCa PDX in vivo model (17). We also evaluated 
whether (1) standard molecular biology tools (such as gene knockdown) can be employed to 
manipulate cell-cell interactions for mechanistic investigations and (2) the effect of dovitinib 
in vivo (17) can be at least in part, reflected in this in vitro PCa PDX model.
Synthesis and characterization of thiolated HA
Sulfhydryl groups were incorporated in HA (620 kDa, Genzyme, Cambridge, MA) by 
reacting HA with a disulfide-containing dihydrazide compound, followed by reduction with 
dithiothreitol, using a previously reported method (20,26). The degree of modification (35–
43%) in thiolated HA was measured (20,26) by 1H nuclear magnetic resonance, and the 
lyophilized product was stored at −20°C under argon prior to use.
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Synthesis of acrylated peptides
Cell-adhesive peptide GRGDS (GenScript USA Inc., Piscataway, NJ) with C-terminal 
amidation was reacted with acrylate-PEG-SVA (3400 g/mol, Laysan Bio Inc., Arab, AL) at 
a molar ratio of 1.2:1 in HEPBS buffer (20 mM HEPBS [Santa Cruz Biotechnology, Inc., 
Dallas, TX], 100 mM NaCl, 2 mM CaCl2, and 2 mM MgCl2) adjusted to pH 8.0 using 0.1N 
NaOH (27). The reaction was allowed to run overnight at 4°C on a shaker pro tected from 
light and then dialyzed for 2 days against ultrapure water using a 3500-Da MWCO dialysis 
membrane (Spectrum Laboratories Inc., Rancho Dominguez, CA) before lyophilization for 
an additional 2 days. MMP-degradable peptide, KGGGPQG↓IWGQGK (GenScript USA 
Inc.) with N-terminal acetylation, herein referred to as PQ (↓ marks the MMP-cleavable 
site), was reacted with acrylate-PEG-SVA at a molar ratio of 1:2.5 using the same protocol. 
Conjugation of acrylate-PEG to the peptides was verified by high-performance liquid 
chromatography (Vydak C18 218TP54 column, Varian Prostar solvent delivery module and 
UV-vis detector) and MALDI-TOF (Bruker AutoFlex II). The lyophilized solids were stored 
at −20°C prior to use.
MDA PCa 118b PCa PDX in vivo propagation and processing
The MDA PCa 118b PDX (25) was routinely maintained as subcutaneous tumors in CB-17 
SCID mice (Charles River). Propagation of tumors in mice was conducted under approval 
by the Institutional Animal Care and Use Committee of The University of Texas MD 
Anderson Cancer Center. Following harvest, the tumors were processed for hydrogel 
encapsulation as previously described (21). To obtain sections of MDA PCa 118b PDX in 
bone for histologic characterization, tumor-bearing femurs were prepared and processed as 
previously described (25).
Cell culture
MC 3T3-E1 (ATCC, Manassas, VA) cells were maintained in alpha-MEM (Life 
Technologies, Grand Island, NY) containing 10% (v/v) FBS and in the presence of 100 
U/mL penicillin and 100 µg/mL streptomycin at 37°C and 5% CO2.
Preparation of cell-laden hydrogel constructs
To prepare the MDA PCa 118b-only constructs, following our previously established 
protocol (21), tumor cell aggregates that formed in suspension were mixed with thiolated 
HA dissolved in PBS to 10 mg/mL. Each MDA PCa 118b-only construct was prepared with 
a theoretical encapsulation density of 300,000 cells (21). Next, acrylate-PEG-GRGDS (73.7 
mg/mL) and acrylate-PEG-PQ-PEG-acrylate (37.0 mg/mL) dissolved in PBS were added to 
the mixture at a volume ratio of 4:1:1 (thiolated SH: acrylate-PEG-GRGDS: acrylate-PEG-
PQ-PEG-acrylate). Final concentrations of GRGDS and PQ in each resulting 42-µL 
hydrogel construct were 3 mM and 0.73 mM, respectively. The tumor cell–hydrogel mixture 
was then pipetted into custom-made PDMS molds as previously described (21) and allowed 
to cross-link for 1 h before immersion in cell culture medium and incubation overnight. 
Cell-laden hydrogel constructs were transferred into 12-well plates the next day. Medium 
was exchanged every 2 days. MC 3T3-E1 mono-culture constructs were prepared in a 
similar manner with encapsulation density of 100,000 cells per construct. To prepare the co-
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culture constructs, a theoretical encapsulation density of 300,000 tumor cells and actual 
density of 100,000 MC 3T3-E1 cells per hydrogel construct was used. A 1:1 (v/v) mixture of 
DMEM/F-12 and alpha-MEM medium supplemented with 2% (v/v) FBS was used for all 
studies.
Immunocytochemistry
As described previously (21), cell-hydrogel constructs in 12-well plates were washed with 
PBS, fixed with 4% (v/v) paraformaldehyde for 10 min at room temperature, and processed 
for immunostaining as described in Supplementary Materials.
Cell viability and growth
Cell viability was evaluated using the LIVE/DEAD viability/cytotoxicity kit (Life 
Technologies) per the manufacturer’s instructions. At the designated time point, cell-
hydrogel constructs were incubated in 400 µL of 2 µM calcein-AM and 4 µM ethidium 
homodimer in PBS for 40 min at 37°C on a shaker before confocal imaging. To assess 
growth, the Quant-iT PicoGreen dsDNA quantification assay (Life Technologies) was used 
per the manufacturer’s instructions as described in Supplementary Materials.
Quantitative PCR
At the designated time point, cell-hydrogel constructs were collected into microcentrifuge 
tubes. Then 500 µL of Trizol (Life Technologies) was added, and an 18-gauge needle and 1-
mL syringe were used to mechanically dissociate the hydrogel constructs. Samples were 
then stored at −80°C and processed for RNA isolation, cD NA synthesis, and real-time PCR 
per the manufacturers’ instructions (Supplementary Materials).
Dovitinib studies
MDA PCa 118b-only, MC 3T3-E1-only, and co-culture constructs were prepared and 
cultured for 4 days. Dovitinib (Novartis, Pharma AG) was dissolved in fresh medium (0, 
500, or 1000 nM) and added to the constructs. Cells were incubated in dovitinib-containing 
medium for an additional 4 days with one medium change. At the designated time point, 
constructs were collected and stored at −80°C before the dsDNA quantification assay was 
run or processed for RNA isolation. DNA content was quantified in a repeat experiment 
under identical conditions. Within each study, measured DNA contents from each group (n 
= 4) were normalized against the average DNA content of the MC 3T3-E1-only untreated 
group, and values from the two studies were combined (n = 8) and averaged.
Fgfr1-knockdown MC 3T3-E1 studies
Fgfr1-knockdown MC 3T3-E1 cells and the corresponding controls were prepared using the 
ON-TARGETplus Mouse Fgfr1 (14182) siRNA–SMARTpool and ON-TARGETplus 
nontargeting Pool (GE Dharmacon, Lafayette, CO) in the presence of HiPerFect transfection 
reagent (Qiagen, Valencia, CA) according to the manufacturers’ protocols. MC 3T3-E1 cells 
were incubated with 30 nM of siRNA and the HiPerFect transfection reagent for 3 days 
before hydrogel encapsulation either alone or with the MDA PCa 118b cells. At each 
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designated time point, constructs were collected and stored at −80°C before the dsDNA 
quantification assay was run or processed for RNA isolation.
Statistical methods
Data are expressed as mean ± standard deviation. Differences between paired data were 
tested using Student’s t test. For the dovitinib study (measured DNA content), one-way 
ANOVA and then Student’s t test were used. For the Fgfr1-knockdown MC 3T3-E1 study 
(measured DNA content), ANOVA was performed at each time point to investigate whether 
cellularity differed between Fgfr1-knockdown MC 3T3-E1 cells and scrambled controls and 
between Fgfr1-knockdown MC 3T3-E1 cells and scrambled controls co-cultured with MDA 
PCa 118b cells. Differences were considered significant at p < 0.05.
Results
PDX-derived PCa cells and osteoblastic cells co-encapsulated in 3D hydrogel mimic in 
vivo tumor organization
With the goal of modeling the PCa cell-osteoblast interaction in vitro, we co-encapsulated 
MDA PCa 118b PDX-derived PCa tumoroids with MC 3T3-E1 osteoblastic cells within an 
engineered 3D hydrogel containing integrin-binding and MMP-degradable peptide 
sequences (Fig. 1). MDA PCa 118b is a PCa xenograft model that we previously established 
from bone metastases in a patient with castration-resistant PCa (25). The use of mouse-
derived MC 3T3-E1 cells enabled the facile separation of gene expression trends from tumor 
and stroma in our co-culture system. In the absence of either the integrin-binding or MMP-
degradable peptide, MC 3T3-E1 cells do not spread when encapsulated in hydrogels. Given 
the poor adherence of PDX-derived PCa cells to tissue culture plastic and their resulting 
tendency to form aggregates in suspension, we pre-generated tumoroids highly enriched for 
human PCa cells and depleted of mouse fibroblasts (21) prior to hydrogel encapsulation. 
Within this hydrogel matrix, the MC 3T3-E1 cells began to spread 1 day after encapsulation 
and remained spread through 6 days in culture, while the PCa tumoroids remained largely as 
compact multicellular aggregates (Fig. 2A). When MC 3T3-E1 cells were co-cultured with 
MDA PCa 118b tumoroids, the MC 3T3-E1 cells also began to spread 1 day after 
encapsulation, and these cells extended their osteoblastic processes towards and around the 
tumoroids over time, with this effect most evident at day 6 in culture (Fig. 2A). To better 
visualize this interaction, representative hydrogel constructs were immunostained for 
epithelial cell adhesion molecule (EpCAM) and vimentin to distinguish the epithelial tumor 
cells from the mesenchymal osteoblastic cells (Fig. 2, B and C). As shown in Fig. 2C, while 
the two cell populations were largely separate at day 1 in co-culture, progressive physical 
association of the MC 3T3-E1 cells and MDA PCa 118b tumoroids was observed over time, 
culminating in envelopment of the tumoroids by osteoblastic processes at day 6 (Fig. 2C). 
Quantification of the association of vimentin+ cells with PCa tumoroids, in both 118b 
monoculture and co-culture, confirmed this rapid physical association (Fig S1). Comparison 
of the resulting structural organization in 3D co-culture (Fig. 2D) with the structural 
organization of MDA PCa 118b PDXs grown intrafemorally (Fig. 2E) indicated that our 3D 
co-culture model closely recapitulated the architectural arrangement of the two cell types in 
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vivo, i.e., a tumor mass surrounded by osteoblasts on the periphery within a mineralized 
matrix.
PDX-derived PCa cells co-cultured with osteoblastic cells in 3D hydrogel retain 
proliferative capacity
Given that MDA PCa 118b cells historically exhibit poor viability in culture (25), we next 
determined if our 3D hydrogel system was capable of supporting the viability of 
encapsulated cells over time. Both in mono-culture and in co-culture, the MDA PCa 118b 
and MC 3T3-E1 cells remained viable for at least 6 days in culture (Fig. 3A). To determine 
whether our 3D PCa co-culture model maintains tumor proliferative potential and exhibits 
growth characteristics necessary for drug testing, especially testing of drugs that target 
actively dividing cells, we evaluated the growth profile of the cultures by measuring the 
tumoroid size distribution over time, as well as by measuring DNA content (as an indirect 
indicator of cell number). Whether in mono- or co-culture, we observed an increase in 
tumoroid size over time (Fig. S2). Notably, the DNA content of the MDA PCa 118b-only 
cultures, the DNA content of the MC 3T3-E1-only cultures, and the sum of these two values 
were consistently lower than the DNA content of the actual co-cultures (Fig. 3B), indicating 
a greater-than-additive effect of the PCa cell–osteoblastic cell interaction. Further, to 
confirm that the tumor cells remained proliferative in our hydrogel system, we 
immunostained for Ki-67. Expression of Ki-67 was detected in the MDA PCa 118b cells at 
all time points (Fig. 3C).
PDX-derived PCa cells co-cultured with osteoblastic cells in 3D hydrogel retain the 
characteristics of the tumor of origin
A unique feature of MDA PCa 118b cells is their ability to trigger robust osteoblastic 
reactions when implanted either orthotopically in bone or ectopically as subcutaneous 
tumors (25). We next investigated if the PDX cells retained their osteogenic capacity when 
grown in our 3D hydrogels. Co-culture of MDA PCa 118b cells with MC 3T3-E1 
osteoblastic cells increased transcript levels of osteoblast-enriched markers osteocalcin, 
bone sialoprotein, and alkaline phosphatase (ALP) in the MC 3T3-E1 cells (Fig. 3D), 
indicating that the MDA PCa 118b cells retained their native bone-forming phenotype. 
Further, we determined whether the hydrogel-encapsulated MDA PCa 118b cells expressed 
FGFR1 and FGF9, both of which are highly expressed by these cells in vivo (Fig. 3, E and 
F). Immunostaining of the hydrogel constructs for FGFR1 and FGF9 revealed that the MDA 
PCa 118b cells expressed both phenotypic markers in our 3D hydrogel system (Fig. 3, E and 
F).
PDX-derived PCa cells cultured in 3D hydrogel induce stromal Fgfr1 expression as 
observed in vivo
To discriminate gene expression in our human tumor–mouse osteoblast co-culture model, 
we used human- and mouse-specific PCR primers to probe for several signaling components 
in the FGF axis: FGFR1-4, FGF2, FGF9, and FGFR substrate 2a. MDA PCa 118b tumor 
cells in co-culture had gene expression similar to that of MDA PCa 118b cells in mono-
culture (Fig. S3). In contrast, MC 3T3-E1 cells co-cultured with MDA PCa 118b cells had 
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significantly increased transcript levels of Fgfr1 (p = 0.001) and Fgfr1-IIIc isoform (p = 
0.006) (Fig. 4A), a finding strikingly similar to the changes seen in vivo (17). Additionally, 
in MC 3T3-E1 cells co-cultured with MDA PCa 118b cells, we observed a slight increase in 
Fgf2 (p = 0.057) and decrease in Fgfr4 (p = 0.098) (Fig. 4A). Expression levels of other 
FGF signaling components in the MC 3T3-E1 cells are shown in Fig. S4. Together, these 
results indicated that our 3D PCa PDX co-culture model closely recapitulates the FGFR-
mediated cross-talk between PCa cells and osteoblasts in vivo.
Cross-talk between PDX-derived PCa cells and osteoblastic cells is at least partially 
mediated by FGFR1
To better understand the complex network of tumor-stromal interactions in vivo, we 
investigated the role of osteoblast FGFR1 in promoting tumor growth by knocking down 
this receptor in the MC 3T3-E1 cells (Fig. 4B). We observed that at day 6, the cellularity of 
co-cultures of MDA PCa 118b cells and Fgfr1-knockdown MC 3T3-E1 cells was 
significantly lower (p = 0.034) than the cellularity of co-cultures of MDA PCa 118b cells 
and MC 3T3-E1 cells transfected with control siRNA but still greater than the sum of the 
cellularity values for the mono-cultures (Fig. 4C). This greater-than-additive effect was 
observed despite suppressed transcript levels of Fgfr1 at day 6 (Fig. 4B). This observed 
decrease in cellularity of the co-cultures of MDA PCa 118b cells and Fgfr1-knockdown MC 
3T3-E1 cells as compared to the controls corroborates with our previous in vivo study, 
where FGFR1 was found to be a significant mediator of the PCa cell-bone cell interaction 
(17).
FGFR inhibitor dovitinib decreases the cellularity of co-cultures of PDX-derived PCa cells 
and osteoblastic cells
Given that our previous study suggested that dovitinib, an FGFR inhibitor, mediated an 
antitumor effect in the in vivo MDA PCa 118b PDX model partly by blocking the PCa cell–
bone cell interaction (17), we next sought to evaluate the effect of dovitinib in our 3D co-
culture model. We found that while dovitinib at 1000 nM did not reduce the cellularity of 
MDA PCa 118b-only and MC 3T3-E1-only mono-cultures as compared to the untreated 
controls, dovitinib did significantly reduce the cellularity of the co-cultures by 26%, 
compared to the untreated controls (p = 0.014) (Fig. 4D). We also investigated the 
biochemical changes in the dovitinib-treated cells by probing for FGFR1 and Fgfr1 
transcript levels using species-specific primers. No reduction in either mouse or human 
transcripts was observed with increasing dovitinib concentrations (Fig. 4E). This contrasts 
with our previous in vivo findings that FGFR1 and Fgfr1 transcript levels were reduced in 
both the tumor and bone stroma of tumor-bearing bones in dovitinib-treated animals (17). 
Given that FGFR blockade with dovitinib was associated with an improvement in bone 
quality in our previous in vivo study (17), we probed for transcript levels of a well-
established marker of osteogenic activity, ALP, in dovitinib-treated MC 3T3-E1 cells. We 
found that ALP levels increased with increasing dovitinib concentrations (Fig. 4F). Taken 
together, these findings suggest that our co-culture model recapitulates two key responses to 
dovitinib seen in vivo, i.e., reduction in the size of the tumor microenvironment and 
osteogenesis.
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Discussion
Increasing recognition of the dependence of cancer cells on their stromal environment has 
shifted the focus of researchers toward co-targeting tumor and stroma (14). For PCa, a 
highly microenvironment-driven cancer, few preclinical models reflect the predominantly 
bone-forming or osteogenic phenotype of the disease (28). Using the MDA PCa 118b PDX 
model (25), we previously found that use of dovitinib to interfere with the FGFR-mediated 
stromal-epithelial interaction in bone is a promising co-targeting strategy (17). In this 
follow-up study, we asked if we could develop an in vitro PCa PDX model that recapitulates 
the molecular mechanisms governing the PCa cell–stromal cell interaction and allows the 
investigator to efficiently control and manipulate the cancer cell microenvironment. 
Leveraging our ability to generate tumor cell–enriched PDX-derived PCa tumoroids in vitro, 
we co-encapsulated PCa tumoroids derived from MDA PCa 118b PDXs with MC 3T3-E1 
osteoblastic cells within a 3D hydrogel. This approach yielded a striking in vivo–like re-
creation of the spatial organization of tumor cells with osteoblasts in bone, maintained cell 
viability and proliferative capacity, and remarkably recapitulated the FGFR-mediated PCa 
cell–stromal cell cross-talk observed in vivo.
Alternative culture systems such as spheroid culture or basement membrane extracts have 
been reported as feasible systems for primary tumor cell culture ex vivo (9,11,29) but 
inherently provide the investigator with little control over the in vitro cancer cell 
microenvironment. With matrix design considerations such as biological activity and tunable 
properties (structural, mechanical, and composition), we previously showed that HA 
matrices are highly supportive of PDX culture in vitro, able to maintain long-term cell 
viability with retention of phenotype (21). However, HA-only hydrogels poorly support 
mesenchymal cell culture. To co-culture osteoblastic cells with PCa PDX cells, we 
specifically tailored HA hydrogels to include covalently bound integrin-binding and MMP-
degradable peptidic modules, the combination of which enables precise manipulation of 
cell-cell and cell-matrix interactions and permitted our novel PCa cell-osteoblastic cell co-
culture.
Compared to bone metastases from other cancers in which osteoblasts are few or absent, 
PCa bone metastases are characterized by a significant presence of osteoblasts adjacent to 
PCa cells as revealed by histopathological analysis (18). Indeed, when MDA PCa 118b 
PDXs are implanted intrafemorally, robust osteoblastic reactions mimicking characteristics 
of the human tumor of origin are observed, with osteoblasts present in the bone matrix near 
the injected tumor cells (25). Similarly, ectopic bone formation is observed around 
subcutaneously grown MDA PCa 118b PDX tumors (25). These observations indicate that 
close proximity of PCa cells to osteoblasts is a unique characteristic of PCa, and the strong 
osteoinductive capacity of the MDA PCa 118b PDXs underscores the well-established 
dependency of PCa on osteoblasts in PCa osteoblastic metastasis (18). In our model, MC 
3T3-E1 cells extended cellular processes towards co-encapsulated PDX tumoroids and often 
enveloped the tumoroids completely, mimicking the spatial organization of MDA PCa 118b 
PDXs with osteoblasts in vivo. Our 3D model will thus enable future detailed examination 
of PCa cell–osteoblastic cell contact mechanisms and their impact on tumor progression.
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Osteogenesis driven by MDA PCa 118b PDXs in vivo has been attributed to secreted 
paracrine factors, such as FGF9 and bone morphogenetic protein (BMP)-4, that induce 
osteoblast proliferation and differentiation (25,28,30). The observed increase in transcript 
levels of osteoblast markers (osteocalcin, bone sialoprotein, and ALP) in the co-cultured MC 
3T3-E1 cells suggests that MDA PCa 118b cells in our model retained their inherent ability 
to induce bone formation. Additionally, the greater-than-additive effect of co-culture on 
cellularity and maintenance of proliferative capacity in the MDA PCa 118b cells is likely 
reflective of the co-stimulatory PCa cell–osteoblast relationship, which involves several 
growth factors, including FGFs, BMP-2, and insulin-like growth factor (17,18,25,30–32), 
further supporting the notion that the PCa-osteoblast cross-talk is recapitulated in our in 
vitro model. This is an important feature of our model as PDXs typically cannot be 
propagated outside the murine host.
Among the targeted therapies in preclinical and clinical development for recalcitrant 
advanced PCa, FGF signaling blockade has emerged as a rational therapeutic strategy (33–
35). Aberrant FGF signaling regulates many mechanisms, including mitogenesis, 
differentiation, angiogenesis, survival, and invasiveness, and contributes to PCa progression 
and metastasis (25,33,34). Examples include demonstrated osteoblast proliferation in 
response to FGF9 produced by MDA PCa 118b cells and overexpression of FGFR1 in PCa, 
especially in MDA PCa 118b cells (17,25). In this study, we established that hydrogel-
encapsulated MDA PCa 118b cells maintained their expression of FGFR1 and FGF9 when 
cultured in vitro, indicating that our hydrogel system preserves salient features of the FGF 
axis in these tumor cells necessary for accurate in vitro modeling of FGF signaling. 
Furthermore, we showed that our co-culture model strikingly recreated the intercellular 
cross-talk and stromal changes that occur when MDA PCa 118b cells are grown in bone. 
Using an orthotopic mouse model of MDA PCa 118b, we previously found that levels of 
stromal Fgfr1 and Fgf2 were increased and the level of Fgfr4 was decreased in tumor-
bearing femurs compared to the contralateral sham-injected femurs (17). While the exact 
molecular mechanisms governing the induction of Fgfr1 in osteoblasts and the implications 
of such Fgfr1 induction are unknown, these changes observed in vivo and in our co-culture 
model fit into the current paradigm describing the PCa-osteoblast relationship, in which 
FGFR1 and FGF2 are key mediators of the interaction and fuel both PCa and osteoblast 
growth in a co-stimulatory relationship (33).
To confirm that our 3D PCa PDX in vitro model permits rapid and controlled examination 
of specific tumor-stromal interactions within the complex in vivo tumor microenvironment, 
we performed a proof-of-concept experiment in which we knockdowned Fgfr1 in the MC 
3T3-E1 cells to investigate the contribution of osteoblast FGFR1 to tumor growth. The 
suppressed cellularity in co-cultures with Fgfr1-knockdown MC 3T3-E1 cells indicates that 
FGFR1 plays a vital role in the PCa-osteoblast interaction, as suggested in our previous 
study (17). Fgfr1 manipulation did not entirely abrogate the increased cellularity in co-
culture, likely because of subtotal knockdown in the MC 3T3-E1 cells and the certain 
presence of multiple other redundant cooperative pathways that moderate the PCa-stromal 
interaction (18).
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In our previous study, dovitinib, a receptor tyrosine kinase inhibitor of FGFR and vascular 
endothelial growth factor receptor, exhibited remarkable clinical efficacy in a subset of 
patients with castration-resistant PCa and bone metastases (17). The antitumor effect was 
achieved indirectly by co-targeting the stromal compartment in bone, highlighting the 
therapeutic potential of disrupting the neoplastic epithelial-stromal interaction in PCa bone 
metastases. In contrast to the decrease in co-culture cellularity, the lack of response to 
dovitinib treatment in the PCa-only and osteoblastic cell–only monocultures suggests that 
our model reflects the tumor-stromal targeting ability of dovitinib in vivo (17). Furthermore, 
the increase in ALP transcript levels observed in our co-cultures suggests that FGFR 
signaling blockade promotes osteoblastic differentiation, which may account for the 
improvement of bone quality observed in vivo (17).
Given that dovitinib-induced changes in Fgfr1 transcript levels were absent in our 3D co-
culture, we propose that other cells in the tumor microenvironment contributed to the 
suppressive effect of dovitinib on Fgfr1 transcript levels previously seen in vivo. Notably, 
the observed reduction in stromal Fgfr1 in vivo was based on a collective measure of Fgfr1 
levels in all stromal cells in bone given that entire mouse femurs were analyzed (17). 
Several cell types within bone express FGFR1 (36); indeed, we previously demonstrated that 
the antitumor effect of dovitinib could be ascribed partially to the antiangiogenic activity of 
the drug, given that endothelial cells also express FGFR1 (17). Current work in our 
laboratories seeks to increase the cellular complexity of our 3D hydrogel co-culture models 
to include elements of the vasculature and innate immune system. Although the current 
model is limited by the use of mouse-derived osteoblastic cells to model the PCa-osteoblast 
interaction, studies are under way to develop a human-only system. Our modular system will 
facilitate mechanistic studies that systematically dissect the complex effect of dovitinib in 
vivo by investigating the role of different stromal cell types on overall drug efficacy.
In conclusion, using a bottom-up approach with the capacity for engineered complexity, we 
established an in vitro auxiliary to an established murine-host PCa PDX model. Our 3D 
modular hydrogel system enables rapid, controlled mechanistic studies aimed at 
deconvoluting complex in vivo tumor-stroma interactions. This study demonstrates 
remarkable consistency in tumor architecture, phenotype, and tumor-stromal signaling 
between the patient’s tumor, the corresponding PDX model, and our in vitro PDX model. 
Future studies may benefit from this translational approach of employing high fidelity PDX 
cells in controlled 3D in vitro systems to support rapid interrogation of complex in vivo and 
clinical findings.
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Schematic of 3D hydrogel system and co-culture fabrication. (A) The hydrogel system 
comprises thiolated HA and acrylate-functionalized peptides, GRGDS (integrin-binding) 
and PQ (MMP-sensitive). (B) PDX tissue harvested from the animal is digested and then 
plated in 6-well plates to allow formation of tumor aggregates. Resulting tumoroids are 
collected and then co-encapsulated with osteoblastic cells.
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Fig. 2. 
PCa cell–osteoblastic cell organization in co-culture. (A) Bright-field images of MDA PCa 
118b-only cultures (PCa), MC 3T3-E1-only cultures (OB), and co-cultures (CO) obtained on 
day 1 (D1), day 3 (D3), and day 6 (D6). Scale bars = 100 µm. (B and C) EpCAM and 
vimentin expression were used to show the EpCAM-positive (green) tumor cells and the 
vimentin-positive (red) osteoblastic cells in (B) PCa-only and OB-only mono-cultures and 
(C) co-cultures at D6. Physical association of the osteoblastic cells with the tumor cells was 
most evident at D6. Scale bars = 100 µm. (D) 3D volume rendering of an osteoblast-
wrapped PCa tumoroid in co-culture. Scale bar = 100 µm. (E) Hematoxylin-eosin-stained 
sections of intrafemorally grown MDA PCa 118b PDX. T = tumor, M = bone matrix; black 
arrow indicates osteoblasts. Scale bar left image = 100 µm; scale bar right image = 50 µm.
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Fig. 3. 
Growth profile and preservation of in vivo tumor phenotype in co-culture. (A) MDA PCa 
118b-only cultures (PCa), MC 3T3-E1-only cultures (OB), and co-cultures (CO) processed 
under the LIVE/DEAD viability assay, in which green staining indicates viable cells and red 
staining indicates nonviable cells. Cells in mono- or co-cultures were viable at day 6 (D6). 
Scale bars = 100 µm. (B) DNA content of actual co-cultures (CO) was consistently higher 
than the sum of DNA content of mono-cultures (PCa + OB). N = 4. (C) MDA PCa 118b 
cells were positive for Ki-67 at all measured time points in culture. Shown are 
immunostained co-culture constructs at D1 and D6. (D) Transcripts encoding osteocalcin, 
bone sialoprotein (BSP), and alkaline phosphatase (ALP) relative to GAPDH in MC 3T3-E1 
cells (D6) were higher in co-culture (CO) than in mono-culture (OB). N = 4. *p < 0.05. (E 
and F) MDA PCa 118b cells retained expression of (E) FGFR1 and (F) FGF9 in the 3D co-
culture model (D6). Constructs were co-stained for EpCAM (green) to identify the tumor 
cells in co-culture. Scale bars = 100 µm. MDA PCa 118b cells grown in bone (right-most 
panel) express (E) FGFR1 (scale bar = 50 µm) and (F) FGF9 (scale bar = 100 µm).
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Fig. 4. 
Manipulation of FGFR-mediated biochemical cross-talk between PCa and osteoblastic cells 
in co-culture. (A) Transcripts encoding FGF signaling components in MC 3T3-E1 cells, 
relative to GAPDH. N = 4. Differences in levels of Fgfr1, Fgfr1-IIIc, Fgfr4, and Fgf2 
transcripts at day 6 (D6) were observed between MC 3T3-E1 cells in mono-cultures (OB) 
and MC 3T3-E1 cells co-cultured (CO) with MDA PCa 118b cells. *p < 0.05. (B) 
Transcripts encoding Fgfr1 in the MC 3T3-E1 cells (relative to GAPDH) under various 
conditions. N = 3. *p < 0.05. Fgfr1-knockdown MC 3T3-E1 cells (OB-KD) and scrambled 
controls (OB-CONT) were co-cultured with MDA PCa 118b cells (CO-KD and CO-CONT, 
respectively). (C) DNA contents of the cultures in (B) and the other cultures indicated in the 
figure were measured over time. N = 4. Average DNA content of CO-KD cultures was 
lower than that of the CO-CONT cultures at D6. Average DNA content of CO-KD cultures 
was higher than the sum of the DNA content of mono-cultures (PCa + OB-KD), similar to 
what was observed with the CO-CONT cultures (compared to summed PCa + OB-CONT 
values), despite suppressed levels of Fgfr1 at D6, as shown in (B). (D) Normalized DNA 
content of dovitinib-treated mono-cultures (PCa and OB) and co-cultures (CO). *p < 0.05. 
Results shown are a combination of two identically performed studies. N = 8. (E) 
Transcripts encoding human FGFR1 and mouse Fgfr1 (relative to GAPDH) in co-cultures in 
the presence of increasing dovitinib concentration. N = 3. (F) Transcripts encoding mouse 
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ALP (relative to GAPDH) in mono-cultures and co-cultures in the presence of increasing 
dovitinib concentrations. N = 3. *p < 0.05. Transcript levels of ALP increased with 
increasing dovitinib concentrations.
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